BioWorld-International-2010-09-15
Roche, reMYND in Pact to Develop PD, AD Drugs
Roche, reMYND in Pact to Develop PD, AD Drugs
Roche AG and reMYND will join forces to develop two classes of compounds against Parkinson's disease and Alzheimer's disease. The total deal is worth as much as $637 million to reMYND as milestones are met. (BioWorld International)

